KIRhub 2.0
Sign inResearch Use Only

JAK1

Sign in to save this workspace

UniProt P23458 · PDB · AlphaFold · Substrate: pEY · Clone: aa 866-1154

Top inhibitors

#DrugInhibitionResidualKISSGini
1Pralsetinib99.1%0.9%93.430.643
2Abrocitinib98.7%1.3%99.500.581
3Baricitinib98.1%1.9%97.990.616
4Ponatinib98.0%2.0%78.230.534
5Upadacitinib97.3%2.6%97.980.663
6Repotrectinib96.9%3.1%84.210.608
7Ruxolitinib96.7%3.3%98.250.592
8Tenalisib96.4%3.6%97.980.702
9Umbralisib96.4%3.6%98.740.670
10Ripretinib96.0%4.0%92.950.674
11Tofacitinib95.2%4.8%99.250.684
12Fedratinib94.2%5.8%96.210.576
13Defactinib93.7%6.3%92.680.450
14Entrectinib93.3%6.7%93.690.671
15Tucatinib92.7%7.3%99.750.652
16Alpelisib92.2%7.8%97.220.720
17Apatinib88.7%11.3%97.730.704
18Pacritinib87.2%12.8%88.640.452
19Vemurafenib85.5%14.5%96.490.598
20Midostaurin85.3%14.7%78.640.500

Paralog block

JAK1, JAK2, JAK3

JAK1JAK2JAK3

EMT expression

  • Mesenchymal log2(TPM+1): 6.06
  • Epithelial log2(TPM+1): 4.89
  • Fold change: 1.17
  • Status: Upregulated

Selectivity landscape vs inhibition on JAK1

Each point is one of the 92 approved drugs; color = inhibition % on JAK1.

3D structure

Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.

Annotations

Sign in to read and post annotations.

Loading…